知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.022 秒)

    Screening methods and the use of agents identified using the same
    3.
    发明申请
    Screening methods and the use of agents identified using the same 审中-公开
    筛选方法和使用与使用相同鉴定的药剂

    公开(公告)号：US20040192901A1

    公开(公告)日：2004-09-30

    申请号：US10674456

    申请日：2003-09-30

    发明人： Ralph N. Martins

    IPC分类号： A61K038/16 ,  G01N033/53 ,  A61K038/40

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C12Q1/26 ,  G01N33/573 ,  G01N33/6896 ,  G01N2333/90283 ,  G01N2500/00

    摘要： A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of: (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and (ii) contacting the peptides isolated form step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides; wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease. Peptides identified using the screening method may be used to treat AD, type II diabetes, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE).

    摘要翻译： 一种分离用于用SOD活性的致病剂治疗疾病或病症的候选肽的方法，所述方法包括以下步骤：（i）使多个候选肽与第一药剂与SOD活性接触并引起 疾病或病症并分离结合的肽; 和（ii）使步骤（i）分离的肽与第一试剂结构相关但不含SOD活性的第二试剂接触并分离未结合的肽; 其中从步骤（ii）分离的肽是用于治疗疾病的候选肽。 使用筛选方法鉴定的肽可用于治疗AD，II型糖尿病，Scrapie和Transemissible Spongiform Encephalopathies如Creutzfeldt Jacob病（CJD），变异CJD，Gerstmann Strausler Schinkler综合征和牛海绵状脑病（BSE）。

    Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions
    4.
    发明申请
    Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions 审中-公开
    痕量金属协同作用的铜核苷酸和铜糖苷用于抗衰老和抗病毒组合物

    公开(公告)号：US20040105894A1

    公开(公告)日：2004-06-03

    申请号：US10306948

    申请日：2002-11-29

    发明人： Shyam K. Gupta

    IPC分类号： A61K048/00 ,  A61K038/16 ,  A61K038/40 ,  A61K031/715 ,  A61K033/24

    CPC分类号： A61Q19/08 ,  A61K8/19 ,  A61K31/7135 ,  A61K31/715 ,  A61K38/063 ,  A61K45/06 ,  A61K48/00 ,  A61K2300/00

    摘要： I have discovered that trace metals such as copper, zinc, iron, and manganese that are necessary for the proper functioning of superoxide dismutase (SOD) and other deactivators of active-oxygen molecules (which cause aging of skin and other skin disorders), can be delivered from the topical compositions. This is achieved by the preparation of copper and other trace metal complexes with phosphorylated nucleosides, such as nucleotides, and phosphorylated monosaccharides, such as phosphorylated glycosides which act as small molecular weight (SMW) transporter molecules. These trace metal complexes of nucleotides and glycosides can be prepared by an in-situ method in water, water-miscible organic solvent, or a mixture of water and water-miscible organic solvent from commonly available ingredients in concentrations that are desirable and can be accurately controlled. I have additionally discovered compositions to achieve the transport of copper from the surface layers of skin into the deeper layers of skin utilizing SMW transporter molecules; and the intra-cellular storage of copper ions in the cell, for example in a bound form with glutathione; and the intra-cellular transport of copper from glutathione to SOD apoprotein by metallochaperones; and the supply of energetic molecules, such as ATP, ADP, or phosphorylated saccharides for SOD metallochaperones to perform their intra-cellular metal transfer function. These cosmetic or pharmaceutical compositions are useful for antiaging and antiviral benefits.

    摘要翻译： 我发现，超氧化物歧化酶（SOD）和其他活性氧分子失活剂（导致皮肤老化和其他皮肤病）的正常功能所必需的痕量金属如铜，锌，铁和锰可以 从局部组合物递送。 这通过制备具有磷酸化核苷（例如核苷酸）的铜和其它痕量金属络合物和磷酸化单糖，例如作为小分子量（SMW）转运蛋白分子的磷酸化糖苷来实现。 这些核苷酸和糖苷的这些痕量金属络合物可以通过原位法在水，水混溶性有机溶剂或水和水混溶性有机溶剂的混合物中制备，所述有机溶剂是常用的成分，其浓度是可取的并且可以准确 受控。 我还附加发现了使用SMW转运蛋白分子实现铜从皮肤表层输送到更深层皮肤中的组合物; 以及细胞内铜离子的细胞内储存，例如与谷胱甘肽的结合形式; 并通过金属相关蛋白将铜从谷胱甘肽转移至SOD脱载蛋白; 以及为SOD金属相关蛋白供应能量分子，例如ATP，ADP或磷酸化糖以进行其细胞内金属转移功能。 这些化妆品或药物组合物可用于抗衰老和抗病毒益处。

    Function and application of tob gene in central nervous systems of mammal
    7.
    发明申请
    Function and application of tob gene in central nervous systems of mammal 审中-公开
    在哺乳动物中枢神经系统中tob基因的功能和应用

    公开(公告)号：US20040242462A1

    公开(公告)日：2004-12-02

    申请号：US10469483

    申请日：2004-07-06

    发明人： Jing Naihe ,  Mei Lei Jin

    IPC分类号： C12Q001/68 ,  G01N033/567 ,  A61K038/40

    CPC分类号： G01N33/5091 ,  A61K38/1709 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5023 ,  G01N33/6896 ,  G01N2800/30

    摘要： This invention concerns the mammalian Tob gene and its coding products, as well as its uses in such areas as the diagnosis and treatment of hypomnesia and amnesia. In addition, this invention also concerns pharmaceutical compositions and tonics containing the Tob protein, as well as the uses of Tob in the screening of drugs concerned with improving memory and treating amnesia or raising movement coordination.

    摘要翻译： 本发明涉及哺乳动物Tob基因及其编码产物，以及其在诸如诊断和治疗失眠症和遗忘症等领域中的用途。 此外，本发明还涉及含有Tob蛋白质的药物组合物和补品，以及Tob用于筛选与改善记忆和治疗健忘症或提高运动协调有关的药物的用途。

    Oral lactoferrin in the treatment of sepsis
    8.
    发明申请
    Oral lactoferrin in the treatment of sepsis 审中-公开
    口服乳铁蛋白治疗败血症

    公开(公告)号：US20040152624A1

    公开(公告)日：2004-08-05

    申请号：US10728521

    申请日：2003-12-05

    发明人： Atul Varadhachary ,  Karel Petrak

    IPC分类号： A61K038/40

    CPC分类号： A61K38/40

    摘要： The present invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of lactoferrin alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacterially induced systemic inflammatory response syndrome. In particular it is claimed that the therapeutic use of recombinant human lactoferrin alone or in combination with metal chelators or other therapeutic interventions decreases the mortality due to bacteremia, sepsis, septic shock or related conditions such as ARDS.

    摘要翻译： 本发明涉及通过单独或与标准疗法或金属螯合剂组合口服一种乳铁蛋白组合物来预防或治疗菌血症，败血症，败血症休克或相关病症的方法，以预防或治疗细菌诱导的全身性 炎症反应综合征。 特别地，声称单独或与金属螯合剂或其它治疗干预组合的重组人乳铁蛋白的治疗用途降低了由于菌血症，败血症，败血症休克或诸如ARDS的相关病症引起的死亡率。

    Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
    9.
    发明申请
    Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression 审中-公开
    铁螯合或消除以减少神经变性或帕金森病进展

    公开(公告)号：US20040101521A1

    公开(公告)日：2004-05-27

    申请号：US10618444

    申请日：2003-07-11

    申请人： The Buck Institute for Research on Aging

    发明人： Julie K. Andersen

    IPC分类号： A61K048/00 ,  A61K031/47 ,  A61K031/195 ,  A61K038/40

    CPC分类号： A61K31/195 ,  A61K31/47 ,  A61K38/40

    摘要： This invention pertains to the discovery that elevated level of free iron causal in the onset and/or progression of diseases characterized by neural degeneration (e.g., Parkinson's Disease). It was also discovered that lowering free iron levels can inhibit (e.g. reduce or eliminate) the onset and/or progression of one or more symptoms of such diseases. Thus, in one embodiment this invention provides a method of inhibiting neural degeneration in a mammal. The method involves reducing free iron levels in a neural tissue of said animal in an amount sufficient to inhibit neural degeneration in said neural tissue.

    摘要翻译： 本发明涉及以神经变性为特征的疾病（例如帕金森病）发作和/或进展中升高的游离铁因子水平的发现。 还发现，降低游离铁水平可以抑制（例如减少或消除）这种疾病的一种或多种症状的发作和/或进展。 因此，在一个实施方案中，本发明提供了抑制哺乳动物神经变性的方法。 该方法包括以足以抑制所述神经组织中的神经变性的量降低所述动物的神经组织中的游离铁水平。